Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration?

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) is a major cause of central vision loss in persons over 55 years of age in developed countries. AMD is a complex disease in which genetic, environmental and inflammatory factors influence its onset and progression. Elevation in serum anti-retinal autoantibodies, plasma and local activation of complement proteins of the alternative pathway, and increase in secretion of proinflammatory cytokines have been seen over the course of disease. Genetic studies of AMD patients confirmed that genetic variants affecting the alternative complement pathway have a major influence on AMD risk. Because the heterogeneity of this disease, there is no sufficient strategy to identify the disease onset and progression sole based eye examination, thus identification of reliable serological biomarkers for diagnosis, prognosis and response to treatment by sampling patient's blood is necessary. This review provides an outline of the current knowledge on possible serological (autoantibodies, complement factors, cytokines, chemokines) and related genetic biomarkers relevant to the pathology of AMD, and discusses their application for prediction of disease activity and prognosis in AMD.

Original languageEnglish (US)
Pages (from-to)231-236
Number of pages6
JournalAutoimmunity Reviews
Volume16
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Macular Degeneration
Autoantibodies
Biomarkers
Cytokines
Alternative Complement Pathway
Chemokines
Developed Countries
Disease Progression
Complement System Proteins
Pathology
Serum

Keywords

  • Age-related macular degeneration
  • Aging
  • Autoantibodies
  • Autoimmunity
  • Chemokines
  • Complement factors
  • Cytokines
  • Factor H
  • IL-17
  • Retina

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration? / Adamus, Grazyna.

In: Autoimmunity Reviews, Vol. 16, No. 3, 01.03.2017, p. 231-236.

Research output: Contribution to journalReview article

@article{2fda727f2a8a4f0bb05efd9728b21830,
title = "Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration?",
abstract = "Age-related macular degeneration (AMD) is a major cause of central vision loss in persons over 55 years of age in developed countries. AMD is a complex disease in which genetic, environmental and inflammatory factors influence its onset and progression. Elevation in serum anti-retinal autoantibodies, plasma and local activation of complement proteins of the alternative pathway, and increase in secretion of proinflammatory cytokines have been seen over the course of disease. Genetic studies of AMD patients confirmed that genetic variants affecting the alternative complement pathway have a major influence on AMD risk. Because the heterogeneity of this disease, there is no sufficient strategy to identify the disease onset and progression sole based eye examination, thus identification of reliable serological biomarkers for diagnosis, prognosis and response to treatment by sampling patient's blood is necessary. This review provides an outline of the current knowledge on possible serological (autoantibodies, complement factors, cytokines, chemokines) and related genetic biomarkers relevant to the pathology of AMD, and discusses their application for prediction of disease activity and prognosis in AMD.",
keywords = "Age-related macular degeneration, Aging, Autoantibodies, Autoimmunity, Chemokines, Complement factors, Cytokines, Factor H, IL-17, Retina",
author = "Grazyna Adamus",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.autrev.2017.01.005",
language = "English (US)",
volume = "16",
pages = "231--236",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration?

AU - Adamus, Grazyna

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Age-related macular degeneration (AMD) is a major cause of central vision loss in persons over 55 years of age in developed countries. AMD is a complex disease in which genetic, environmental and inflammatory factors influence its onset and progression. Elevation in serum anti-retinal autoantibodies, plasma and local activation of complement proteins of the alternative pathway, and increase in secretion of proinflammatory cytokines have been seen over the course of disease. Genetic studies of AMD patients confirmed that genetic variants affecting the alternative complement pathway have a major influence on AMD risk. Because the heterogeneity of this disease, there is no sufficient strategy to identify the disease onset and progression sole based eye examination, thus identification of reliable serological biomarkers for diagnosis, prognosis and response to treatment by sampling patient's blood is necessary. This review provides an outline of the current knowledge on possible serological (autoantibodies, complement factors, cytokines, chemokines) and related genetic biomarkers relevant to the pathology of AMD, and discusses their application for prediction of disease activity and prognosis in AMD.

AB - Age-related macular degeneration (AMD) is a major cause of central vision loss in persons over 55 years of age in developed countries. AMD is a complex disease in which genetic, environmental and inflammatory factors influence its onset and progression. Elevation in serum anti-retinal autoantibodies, plasma and local activation of complement proteins of the alternative pathway, and increase in secretion of proinflammatory cytokines have been seen over the course of disease. Genetic studies of AMD patients confirmed that genetic variants affecting the alternative complement pathway have a major influence on AMD risk. Because the heterogeneity of this disease, there is no sufficient strategy to identify the disease onset and progression sole based eye examination, thus identification of reliable serological biomarkers for diagnosis, prognosis and response to treatment by sampling patient's blood is necessary. This review provides an outline of the current knowledge on possible serological (autoantibodies, complement factors, cytokines, chemokines) and related genetic biomarkers relevant to the pathology of AMD, and discusses their application for prediction of disease activity and prognosis in AMD.

KW - Age-related macular degeneration

KW - Aging

KW - Autoantibodies

KW - Autoimmunity

KW - Chemokines

KW - Complement factors

KW - Cytokines

KW - Factor H

KW - IL-17

KW - Retina

UR - http://www.scopus.com/inward/record.url?scp=85011301108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011301108&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2017.01.005

DO - 10.1016/j.autrev.2017.01.005

M3 - Review article

C2 - 28137479

AN - SCOPUS:85011301108

VL - 16

SP - 231

EP - 236

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 3

ER -